Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGI226 microparticles for mid-portion Achilles tendinopathy
NL-OMON59971Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jul 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Achilles tendinitis (AT) comparing NGI226 MP with Placebo (2 arms). Primary endpoints: Local and systemic treatment-emergent adverse events, Local tolerability and 3 more. Planned start Jul 2023; status: withdrawn.
02
Drugs
NGI226
03
Conditions
Achilles tendinitis (AT)
Beyond the preview
Go deeper on NL-OMON59971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59971.